Xenon Pharmaceuticals company info

What does Xenon Pharmaceuticals do?
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Their research and development efforts are primarily centered around leveraging proprietary technologies to create drugs that can address conditions such as epilepsy, Parkinson's disease, and other rare neurological diseases. Operating at the cutting edge of medical research, Xenon is dedicated to advancing a pipeline of neurology-focused treatments through clinical trials, with the ultimate objective of delivering new therapeutic options that can significantly improve patient outcomes. The company's commitment to science and medicine drives its pursuit of breakthroughs that can transform the treatment landscape for neurological conditions.
Xenon Pharmaceuticals company media
Company Snapshot

Is Xenon Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Xenon Pharmaceuticals employ?

people
Employees
269

What sector is Xenon Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Xenon Pharmaceuticals?

location pin
Head Office
Vancouver, Canada

What year was Xenon Pharmaceuticals founded?

founded flag
Year Founded
1996
What does Xenon Pharmaceuticals specialise in?
/Pharmaceutical Research /Drug Development /Genetic Therapies /Neurological Disorders /Pain Management /Rare Diseases

What are the products and/or services of Xenon Pharmaceuticals?

Overview of Xenon Pharmaceuticals offerings
XEN1101, a novel Kv7 potassium channel opener designed for the treatment of epilepsy and potentially other neurological disorders.
XEN496, a Kv7 potassium channel opener, specifically formulated for the treatment of KCNQ2 epileptic encephalopathy.
XEN007 (active ingredient flunarizine), a calcium channel blocker being studied for the treatment of various neurological disorders, including hemiplegic migraine.
Partnership with Neurocrine Biosciences to develop treatments for epilepsy, focusing on advancing novel Kv7 potassium channel modulators.
Collaboration with Flexion Therapeutics to develop and commercialize treatments for osteoarthritis, leveraging Xenon's expertise in ion channel modulators.
Research and development in the field of ion channel modulators, aimed at discovering innovative therapies for neurological conditions, emphasizing Xenon's commitment to addressing unmet medical needs.

Who is in the executive team of Xenon Pharmaceuticals?

Xenon Pharmaceuticals leadership team
  • Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
    Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
    President, CEO & Director
  • Ms. Sherry  Aulin
    Ms. Sherry Aulin
    Chief Financial Officer
  • Ms. Andrea  DiFabio J.D.
    Ms. Andrea DiFabio J.D.
    Chief Legal Officer & Corporate Secretary
  • Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.
    Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.
    Chief Commercial Officer
  • Dr. Christopher John Kenney M.D.
    Dr. Christopher John Kenney M.D.
    Chief Medical Officer
  • Ms. Shelley  McCloskey B.A.
    Ms. Shelley McCloskey B.A.
    Executive Vice President of Human Resources
  • Dr. Robin P. Sherrington Ph.D.
    Dr. Robin P. Sherrington Ph.D.
    Executive Vice President of Strategy & Innovation
  • Dr. James R. Empfield Ph.D.
    Dr. James R. Empfield Ph.D.
    Executive Vice President of Drug Discovery